OyaGen, Inc is a drug development biotech company focused on delivering a functional cure to HIV/AIDS to the market

OyaGen has its origins in the science of RNA and DNA editing enzymes, their interactions and their regulation through the academic work of Dr. Harold C. Smith, University of Rochester, Rochester, NY (http:/dbb.urmc.rochester.edu/index.htm). Founded by Dr. Smith in 2003, OyaGen, Inc. holds Intellectual Property (IP) licensed from Thomas Jefferson University, the University of Rochester, Oregon Health Sciences Center and Vybion Inc. in addition to Company's self-generated IP. Initially, OyaGen is...

OyaGen has its origins in the science of RNA and DNA editing enzymes, their interactions and their regulation through the academic work of Dr. Harold C. Smith, University of Rochester, Rochester, NY (http:/dbb.urmc.rochester.edu/index.htm). Founded by Dr. Smith in 2003, OyaGen, Inc. holds Intellectual Property (IP) licensed from Thomas Jefferson University, the University of Rochester, Oregon Health Sciences Center and Vybion Inc. in addition to Company's self-generated IP. Initially, OyaGen is focused on the discovery and development of therapeutics for the treatment of HIV. The Company has identified 5 unique druggable targets on HIV which attack the virus and/or strengthen the innate cell defense. Successful development of drugs that address these targets will offer patients first-in-